226 related articles for article (PubMed ID: 31366979)
1. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
[TBL] [Abstract][Full Text] [Related]
3. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
4. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
6. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
7. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract][Full Text] [Related]
9. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
11. [Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy].
Muneoka K; Shirai Y; Sasaki M; Honma S; Sakata J; Kanda J; Wakabayashi H; Wakai T; Miyazaki M
Gan To Kagaku Ryoho; 2018 Aug; 45(8):1159-1163. PubMed ID: 30158411
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
[TBL] [Abstract][Full Text] [Related]
13. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
14. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract][Full Text] [Related]
15. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
16. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
Kim HJ; Park S; Kim KJ; Seong J
Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
[TBL] [Abstract][Full Text] [Related]
18. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
19. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]